timothy sykes logo
TEM Stock Jumps As ARK, Medtronic, Gilead Fuel AI Healthcare Story Thumbnail
ADD US ONG Google News

TEM Stock Jumps As ARK, Medtronic, Gilead Fuel AI Healthcare Story

MATT MONACO•UPDATED APR. 15, 2026, 5:04 PM ET
Reviewed by Jack Kellogg Fact-checked by Tim Sykes

Tempus AI Inc. stocks have been trading up by 13.41 percent amid heightened investor optimism from its most favorable news coverage.

Candlestick Chart

Live Update At 17:03:38 EDT: On Wednesday, April 15, 2026 Tempus AI Inc. stock [NASDAQ: TEM] is trending up by 13.41%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

TEM has been trading like a momentum rollercoaster. Over the last few weeks, Tempus AI Inc. has ripped from the low $40s to a recent close around $56.41, with the latest session printing a strong move from an open near $50.35 to that high close. For short-term traders, that’s a clean breakout over prior resistance in the mid‑$40s, backed by expanding intraday ranges.

The 5‑minute chart shows steady accumulation throughout the day. TEM held the $50 area early, then marched higher in a series of higher lows and controlled pullbacks, finishing the regular session with buyers still in charge around the $56 level. That kind of trend day often attracts day traders and swing traders scanning for liquid, high‑beta setups.

Under the hood, Tempus AI Inc. is still a high‑growth, loss‑making platform. Revenue runs about $1.27B a year, but margins are sharply negative: EBIT margin sits near ‑17.6% and net margin around ‑19%. Returns on equity and assets are deep in the red, confirming TEM is spending heavily to build scale. On top of that, Tempus AI Inc. trades at roughly 6.5x sales and about 16.8x book, with a current ratio near 3.1 that signals solid liquidity but an aggressive growth profile. For traders, TEM is clearly a story stock: price action is driven more by news, execution milestones, and sentiment than by traditional value metrics.

Why Traders Are Watching TEM Right Now

TEM is suddenly back on a lot of watchlists, and there’s a reason: the news flow lines up cleanly with the price action. Tempus AI Inc.’s joint clinical trial with Medtronic is the kind of catalyst traders dream about. This is not vague AI hype. The Tempus AI Inc. platform helped identify and route severe heart valve disease cases faster, which drove a 40% jump in surgical interventions and a 27% increase in specialist evaluations across 35 hospitals. The market reacted immediately, with TEM trading up roughly 4.3% on that headline.

For a story name, that kind of real‑world outcome matters. It tells traders the AI stack Tempus AI Inc. has built is moving the needle in the clinic, not just in slide decks. When the tape shows a clean uptrend on the same days this data hits, momentum players pay attention.

Then you have the Gilead Sciences news. TEM expanded a multiyear partnership that gives Gilead enterprise‑wide access to its Lens platform and de‑identified multimodal oncology datasets. That reads like a long‑tail, platform relationship: deep integration into big‑pharma R&D rather than a one‑off project. Traders reading between the lines will see Tempus AI Inc. embedding itself in oncology pipelines, which supports a recurring‑revenue style story and helps justify those rich sales multiples.

Layer on ARK Invest. Cathie Wood’s team has been rotating capital out of mega‑cap tech and semiconductors into TEM, turning Tempus AI Inc. into one of ARK’s largest positions even after a drawdown of more than 20% year‑to‑date. That’s a classic contrarian tell. A high‑profile thematic fund is willing to buy the dip on the idea that AI‑driven precision medicine is the next major AI value layer. Traders don’t have to agree with the thesis, but they do need to respect the flows: when a player like ARK builds a top position, liquidity and volatility both tend to spike.

Finally, William Blair’s upcoming diagnostics and testing call tells you institutions are sharpening their pencils on this corner of healthcare. AI‑enabled diagnostics firms like Tempus AI Inc. sit squarely in that spotlight, which usually translates into more research coverage, more models, and—crucially for traders—more earnings‑day volatility. Put it all together and TEM has the ingredients for sustained, news‑driven trading action.

More Breaking News

Conclusion

For active traders, TEM is a pure execution and sentiment story wrapped in an AI‑healthcare narrative. Tempus AI Inc. is not cheap by traditional metrics, and the company is still running meaningful losses with negative returns on equity and assets. But the recent tape says the crowd is willing to pay up when Tempus AI Inc. proves the tech works in the real world and lands deep, strategic partners.

The Medtronic trial results give TEM something concrete to point to: better detection, more surgeries, and faster care. The Gilead expansion shows a major pharma player standardizing on the Tempus AI Inc. platform for oncology R&D. ARK’s rotation into TEM adds fuel, signaling that at least one high‑profile shop views the >20% year‑to‑date slide as an opportunity, not a warning sign.

For short‑term traders, that combination—strong news, institutional buying, and a clean technical breakout—can create powerful momentum swings in both directions. The key is to treat Tempus AI Inc. like any volatile growth name: map key levels, respect liquidity, and cut losers fast if the thesis cracks. As millionaire penny stock trader and teacher Tim Sykes, says, “Cut losses quickly, let profits ride, and don’t overtrade.” As Tim Sykes likes to remind traders, “the market doesn’t care about your opinion, only about price action—react, don’t predict.” This article is for educational and research purposes only and is not investment advice, but TEM has clearly earned its place on the radar for momentum and catalyst‑driven strategies.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading TEM

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”